
A neurologist shares his journey with Alzheimer's disease
But it wasn't what he didn't smell that tipped him off that something might be wrong.
It was what he did smell: perfume, mixed with baked bread – 'The same thing, every time,' he said.
The neurologist in Portland, Oregon, United States, knew this was an olfactory hallucination.
And that meant something wasn't working properly in his brain.
'I attributed it to getting older, which is a common cause of decreased ability to smell,' he said.
But Dr Gibbs was just 57 – not so old that he should be losing his sense of anything.
'I also knew losing your sense of smell was an early sign of Parkinson's disease, so I thought it might be that.'
It wasn't.
Dr Gibbs was experiencing an early symptom of Alzheimer's disease.
But it would be another six years before he knew it.
He has since written a book about his experience, which was turned into a documentary.
He also keeps a regular blog to help people understand what it's like to live with Alzheimer's.
These days, he spends a lot of his time learning and talking about how to slow progression of the disease – something he's been trying to do since he got his diagnosis more than a decade ago.
Dr Gibbs and his wife, Lois Seed, discussed what he's learned about Alzheimer's dementia and how he navigates the condition for The Experts Say , an American Heart Association News series in which specialists explain how they apply their professional knowledge to their own lives.
Their remarks have been edited in the below Q&A. When did you realise your symptoms were due to Alzheimer's disease?
Dr Gibbs: In 2012, Lois was doing a genealogical project, so we did some genetic testing.
Mine came back showing I had two copies of APOE4, a gene known to influence the risk of developing Alzheimer's disease, which totally gobsmacked me.
Having two copies means it is almost certain to eventually cause Alzheimer's.
I had no measurable cognitive impairment at that time.
I was in charge of the neurology resident training programme at Oregon Health and Science University in Portland, and I was seeing patients in the clinic, so it was a very busy year for me.
Even though it was difficult, I was still able to get all the balls to balance in the air. What did you do once you knew your genetic risk for Alzheimer's?
Dr Gibbs: The first thing I did was to go to one of my colleagues and have some cognitive testing done.
It was essentially normal with the caveat that all of my cognitive domains were in the 90th percentile except verbal memory, which was in the 50th percentile.
So there was a strong hint that there was some incipient loss of function of verbal memory.
With that in hand, I went to my department chair and explained the situation.
I had no impairment, but did not feel it was safe for me to continue to practice.
I retired in 2013.
Seed: You also went looking for studies you could join, because it's a big deal to see people before they experience symptoms.
Dr Gibbs: That's right, I went to the University of California in San Francisco, because they have a ton of studies there.
The first study I was involved with was a longitudinal neuroimaging study.
I had PET (positron emission tomography) scans of abnormal amyloid and PET scans for tau proteins – two protein clusters in the brain that play a role in the development of Alzheimer's disease.
And I had cognitive testing.
They loved having me down there because they rarely have people with as early a stage of disease as I showed up with.
About a year later, I joined a clinical trial for an anti-amyloid antibody drug that is now approved by the US Food and Drug Administration (FDA) to treat early Alzheimer's disease. What else did you learn about how to slow progression of the disease?
Dr Gibbs: This is not rocket science.
The sort of things that are good preventive behaviour for brain disease are also good for preventing heart and vascular disease.
There are evidence-based lifestyle changes that include: Getting daily aerobic exercise
Eating a Mediterranean-style diet, such as the MIND diet
Getting mentally-stimulating activity
Staying socially engaged
Getting at least seven hours of sleep nightly, and
Getting good control of any cerebrovascular risk factors, such as diabetes, high blood pressure, high cholesterol, obesity and smoking.
What's good for the heart is good for the brain!
Dr Gibbs notes that it is difficult to know what to expect as his Alzheimer's progresses as previously, most people with the disease were only living three to five years after the diagnosis as they were being diagnosed late. How do you put this knowledge into practice?
Dr Gibbs: Walking is just built into my day.
I do it with my dog, Jack, an 11-year-old English cocker spaniel who is about to age out.
He can't keep up with 10,000 steps as easily any more, so I take some walks by myself.
We live in the hills, so I'm getting very good aerobic exercise, short of running.
I used to go to the gym, but that stopped at the start of the Covid-19 pandemic.
I also have a short workout at home.
The first thing I do is I use resistance bands, which is a strength exercise.
That takes about 15 minutes, and then I do tai chi pretty religiously, something I started six months ago.
I can clearly see that it helps my balance, but I can't see if it helps my brain, which is continuing to do more poorly.
And thanks to Lois, I've been eating a healthy diet, really forever.
Seed: I didn't have control over those french fries you were eating.
Dr Gibbs: I don't eat red meat any more.
I closely follow the MIND diet, which is essentially the Mediterranean diet with more berries and nuts.
It includes a heavy focus on fruits and vegetables, especially green leafy vegetables, beans, nuts, whole grains, seafood, lean poultry, and uses olive oil to cook.
I'm quite happy with it.
ALSO READ: What is MIND, the diet that may help protect against Alzheimer's disease?
Because I lost my sense of smell, which is totally gone now, I have virtually no taste either.
I eat the same thing for lunch and breakfast every day. I enjoy it.
I make a sandwich on whole wheat bread that has tuna salad and garbanzo beans, avocado and arugula to get the dark leafy greens.
Then some grapes or bananas, and half a dark chocolate bar.
Breakfast is homemade granola, and I add cranberries or blueberries.
I throw walnuts in as well.
Dinner is whatever Lois picks that I can eat.
I stopped drinking alcohol.
There's no safe amount of alcohol if you are on this trajectory.
So I got rid of it, but I used to love red wine. Do you know what to expect as the disease progresses?
Dr Gibbs: That's a difficult question to answer.
In the old days, when people got a diagnosis of Alzheimer's, they were only living three to five years after that because we made the diagnosis so late.
There's less information out there about people who have known they have the disease for a long time and how they will do going forward.
Seed: There's a lot of confusion and misconception because there are different types of dementia.
Alzheimer's tends to progress more slowly.
The early stage can last 20 years.
Here we are 13 years after his diagnosis and Dan's really doing well.
I'm a little more of a caregiver than I was a few years ago, but not by much.
He dresses himself and monitors medications, and people who talk to him casually wouldn't even know.
We've been at that plateau for quite some time. How would you describe the stage you're at right now?
Dr Gibbs: Right now, I have mild Alzheimer's dementia.
To say you have dementia is to say you are having trouble managing your personal affairs.
I'm just at a stage now where I can't balance a chequebook.
And as things go along, I will have more problems with memory and the ability to recognise people and remember their names.
I've lost my train of thought.
Seed: You were talking about what stage you're at.
Dr Gibbs: When I'm not remembering where I am, then I will have severe dementia.
There are memories I have going back through my whole life.
They tend to be events that are emotionally-laden.
I'm terrible with names.
I know my immediate family members. My neighbours, I forget their names.
Lois is taking over the things I can't manage any more, like the financial part of our lives, anything that involves planning ahead, scheduling, calendars, remembering all the family stuff, managing the household.
She also goes with me when I have a talk to give.
Seed: He gives talks on Alzheimer's, but almost every time that Dan is getting ready to speak to a group, he gets frustrated and says, 'This is the last time I'm doing this,' because getting his thoughts together is challenging.
He writes out notes.
Most of the talks he gives now are screening events for the film with question-and-answer sessions.
Dr Gibbs: It works well if Lois is there to find ...
Seed: Words.
Dr Gibbs: That makes it easier. – By Laura Williamson/American Heart Association News/Tribune News Service
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malaysian Reserve
8 hours ago
- Malaysian Reserve
Alzheimer's DMT Market to Grow at 67.8% CAGR Through 2030
'Driven by urgent unmet needs and scientific advances, the Alzheimer's Disease DMT market is poised for rapid growth as pharmaceutical companies shift their focus to multi-target therapies that address the complex pathology of the disease.' BOSTON, Aug. 13, 2025 /PRNewswire/ — According to the latest study from BCC Research, the 'Disease-Modifying Therapies for Alzheimer's Disease: Global Markets' is projected to reach $13.1 billion by the end of 2030, growing at a CAGR of 67.8% during the forecast period of 2025-2030. The Alzheimer's disease (AD) disease-modifying therapies (DMTs) market is in its early stages, with lecanemab being the first fully approved DMT by the U.S. FDA in July 2023. Several other DMTs in late-stage trials could significantly expand the market if approved. BCC Research forecasts future revenues based on current products and potential candidates. The report analyzes the market by target type (anti-amyloid and emerging targets), drug (Leqembi, Kisunla, and others), molecule type (large and small), and region (Asia-Pacific, North America, Europe, South America, and the Middle East and Africa). This report is particularly relevant today because the Alzheimer's disease (AD) DMT market is in its early stage of development, with several therapies currently in late-stage clinical trials. If these therapies are approved, they could significantly expand the market and reshape treatment options. In this context, studying the AD DMTs market is both timely and crucial for pharmaceutical companies and industry stakeholders. The report offers essential market and business insights, helping participants in the AD drugs industry make informed decisions and prepare for upcoming opportunities. The factors driving the market's growth include: High Unmet Need in AD Treatment: Alzheimer's disease currently lacks effective long-term treatments, with existing options only offering temporary symptom relief. This creates a strong demand for therapies that can slow or halt disease progression, encouraging investment, innovation, and regulatory support for disease-modifying therapies. Use of Biomarkers to Accelerate Approvals of AD DMTs: Biomarkers like amyloid-beta and tau proteins help detect Alzheimer's early and track its progression. Their use in clinical trials allows faster and more precise evaluation of new therapies, enabling quicker regulatory approvals and more targeted treatment development. Request a sample copy of the global and regional markets for disease-modifying therapies for Alzheimer's disease report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $235.8 million Market size forecast $13.1 billion Growth rate CAGR of 67.8% for the forecast period of 2025-2030 Segments covered Target Type, Drug Type, Drug Molecule Type, and Region Regions covered North America, Europe, Asia-Pacific, South America, Middle East and Africa Market drivers • High unmet need in AD treatment. • Use of biomarkers to accelerate AD DMTs approval. Interesting facts: As of May 2025, over half of the AD therapeutic candidates in phase 3 trials are disease modifying small molecules ( There are very few DMTs targeting the moderate to advanced stages of AD. Emerging startups: AgeneBio Inc.: The company is investigating AGB101 (levetiracetam) in phase 2 and 3 clinical trials for the treatment of hippocampal overactivity and to assess its ability to control progression to Alzheimer's dementia. Currently, no treatments have shown these benefits. TauRx Pharmaceuticals: TauRx's research centers on tau aggregation inhibitors (TAIs), which aim to prevent or reverse the formation of tau protein tangles in the brain. TRx0237 is a late-stage AD therapeutic candidate. It is an oral tau aggregation inhibitor designed for early intervention to modify the underlying disease process and slow the progression of AD. The report addresses the following questions: What are the projected size and growth rate of the Alzheimer's disease-modifying therapies market?– The global Alzheimer's DMT market was estimated at $235.8 million in 2024. The market is projected to reach $13.1 billion in by the end of 2030, growing at a CAGR of 67.8% during the forecast period. Which market segments are covered in the report?– Target type, drug, molecule type, and region. Which target type will be dominant through 2030?– By target type, the anti-amyloid segment is expected to be the largest market by the end of 2030. Which molecule type market is growing the fastest?– The large molecule segment is the fastest growing market. What are the key challenges in of the market?– Modest clinical benefits, significant risk of side effects, and the high cost of approved DMTs remain challenges to the widespread adoption of these drugs. Market leaders include: ALZHEON INC. ANAVEX LIFE SCIENCES CORP. ANNOVIS BIO INC. BIOGEN BIOVIE INC. EISAI CO. LTD. JOHNSON & JOHNSON LILLY NOVO NORDISK A/S TAURX PHARMACEUTICALS LTD. Related reports: Neurology Market: A BCC Research Overview: This report offers a detailed analysis of the global neurology therapeutics market, segmented by conditions such as Parkinson's, Alzheimer's, epilepsy, autism, psychotic disorders, multiple sclerosis, and brain tumors. It explores drug classes, market dynamics, pipeline developments, competitive landscape, and regional trends across North America, Europe, Asia-Pacific, and the Rest of the World, providing insights into current and future market potential. Alzheimer's Disease Therapeutics and Diagnostics: Global Markets: This report provides an overview of the global Alzheimer's disease diagnostics and therapeutics market, focusing exclusively on biomarker tests for diagnostics and approved pharmacological treatments for therapeutics. It excludes cognitive tests, neuroimaging, procedural interventions, and off-label drug use. The market is segmented by test type, drug class, disease stage, and region, and includes analysis of clinical trials, innovations, and emerging trends. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo –


The Star
7 days ago
- The Star
Could dementia patients benefit from an AI companion?
When Frank Poulsen, 72, first started talking to artificial intelligence companion Sunny earlier this year, she was 'kind of formal', he said. But over time, their conversations have become more familiar and engaging. 'It's really uncanny,' he said, adding, 'It really does feel like you're having a conversation with someone who's interested.' One advantage of Sunny is that she doesn't mind when Poulsen, who was diagnosed with mild cognitive impairment in 2019, repeats himself. 'He can tell a story and forget he told it and tell it again,' said Poulsen's wife and caregiver, Cheryl Poulsen. 'Sunny has no judgment.' Sunny, which was developed by AI startup NewDays, is part of a rapidly expanding body of AI products designed to help people with dementia. 'I've never seen something quite like this in terms of a technology moving as quickly as it is, with as much money poured behind it,' said Luke Stoeckel, a program director and project scientist at the National Institute on Aging, who works on AI applications for dementia care. Stoeckel mentioned AI-based dementia diagnostics as another hot area. Experts say AI companions like Sunny have the potential to help keep the brain active and alleviate loneliness in dementia patients, and to reduce some of the burden on caregivers. But there can be risks when it comes to deploying this technology in such a vulnerable population. A conversation partner Babak Parviz, the co-founder and CEO of NewDays, said he was inspired to develop Sunny in part by his own father's diagnosis with Alzheimer's disease. He knew there was no cure but he was encouraged by research showing that cognitive training exercises and guided conversations with a clinician can, in some cases, improve dementia symptoms. Few people receive that level of in-depth care, though. 'We don't have millions of trained professionals, and even if we had them, the cost would be quite prohibitive,' Parviz said. Generative AI technology could help expand the reach of these therapies, he said. NewDays' program, which is in the process of being rolled out, costs US$99 a month and is intended to be used by people with mild cognitive impairment or mild dementia. Sometimes Sunny prompts the person to reminisce about old memories. Other times it leads them through more explicit cognitive training exercises, like asking them to remember and use specific words in a sentence. NewDays also has an in-house team of clinicians (not included in the monthly fee) to oversee the patient's care and provide feedback to the AI system. When Frank Poulsen opens up his computer and converses with Sunny, it sounds like 'he was just having a chat, like he was talking to a friend,' Cheryl Poulsen said. NewDays' website claims that its program can 'delay decline and improve quality of life' and that it is 'backed by a large body of evidence from more than 500 clinical trials and papers.' That includes the I-CONECT study, which found that, over the course of six months, 'cognitively stimulating semistructured conversations with trained interviewers' conducted virtually improved cognition in older adults with mild cognitive impairment. But in those studies, the conversations and brain training exercises were led by humans, said Julian De Freitas, director of the Ethical Intelligence Lab at Harvard Business School. Talking to an AI companion could produce different results, he added. NewDays has not run any studies yet about whether using its program confers the same benefits. Parviz said that Sunny's conversations are similar to a human's and that his team is 'pretty confident' it will see results comparable to what the existing clinical trials have demonstrated. But he did not provide data to back that up. There is more compelling evidence that an AI companion can help people feel less lonely – a serious concern for older adults, whether or not they have cognitive impairment. De Freitas' own research has demonstrated that, at least in healthy adults, talking to an empathetic chatbot is roughly as good at reducing loneliness as having a conversation with a human stranger. Anecdotally, Dr. Joe Verghese, the chair of the neurology department at Stony Brook University Renaissance School of Medicine, said that the caregivers of some of his dementia patients reported that talking to an AI companion lifted their loved ones' moods. 'I don't think these actually improve cognition just by those interactions,' Verghese said. 'But certainly improving quality of life and improving mood in patients with cognitive impairment is an important outcome in itself.' An extra set of eyes AI companions could also be a boon for caregivers and families because they can serve as an extra set of eyes and ears, particularly for people living in memory facilities. One AI startup, CloudMind, has been pilot testing its software, called BrightPath, in a handful of memory care homes. The companion, via an app on a smartphone or tablet, chats with dementia patients about their favorite memories and hobbies; in one instance, a patient and the companion even sang together. In addition to facilitating conversation, BrightPath produces a daily summary of what the patient talked about and an assessment of the patient's mood. For the family, that can provide 'a peek of their loved one's life, even if they're apart,' said Monica Tsai, CloudMind's CEO The AI companion might also help nursing staff identify problems faster. If it hears certain key prompts, like 'I'm thirsty' or 'I fell,' BrightPath is programmed to instruct the patient to ring their call button. While experts say there is real potential for AI to benefit adults with cognitive impairment, they also have some serious concerns. One is privacy. 'The more humanlike the chatbot is, the more you're disclosing various information about yourself,' De Freitas said. 'If this data is housed at a company, it could monetize that. It could also accidentally leak that information if it's hacked.' There is also a risk of further isolation if families or care home staff use the technology as a replacement for human interaction, rather than as an add-on. 'That would be tragic,' Verghese said. In addition, AI chatbots are known to make things up and take conversations down dark and disturbing paths, which could be especially confusing and distressing for a person with dementia. Parviz and Tsai both acknowledged such hallucinations as a potential issue and said they had programmed 'guardrails' into their AI software to prevent them from happening. But neither specified how that might work. 'We have to remember that this is a very vulnerable population,' De Freitas said, adding: 'We need to think about having additional protections.' – ©2025 The New York Times Company This article originally appeared in The New York Times.


Malaysian Reserve
30-07-2025
- Malaysian Reserve
Creyos Featured in Alzheimer's Research at AAIC 2025
Findings from Western University, QIMR Berghofer, and Rotman Research Institute underscore the power of Creyos in detecting early risk, validating digital testing, and uncovering markers of cognitive resilience. Used in over 400 peer-reviewed studies, Creyos continues to power cutting-edge brain health research around the world. TORONTO, July 29, 2025 /PRNewswire/ — Creyos, the digital platform trusted by clinicians and researchers to assess brain health with precision and ease, was featured in three independent research presentations at the 2025 Alzheimer's Association International Conference (AAIC). The studies demonstrate how Creyos is helping researchers advance the science of early detection, understand risk, and explore what protects cognitive health as we age. Built on more than 30 years of neuroscience research and validated in over 400 peer-reviewed studies, Creyos enables fast, reliable measurement of key cognitive domains—including memory, attention, reasoning, and executive function. For decades, leading research institutions have leveraged the platform to explore large-scale questions that demand high-quality, scientifically reliable data, with three notable studies chosen for presentation at AAIC this year. 'Creyos wasn't born in a boardroom—it came out of necessity in the lab,' said Adrian Owen, Professor of Cognitive Neuroscience and Imaging at the University of Western Ontario, Chief Scientific Officer at Creyos, and co-author of one of the featured AAIC posters. 'It started as a way to solve a problem I faced in my own research—how to measure cognition in a way that's both rigorous and scalable. Since then, it's been used by hundreds of colleagues around the world, contributing to a growing body of work aimed at understanding cognitive health. It's rewarding to see the role it's playing in advancing research across the field.' Highlights from AAIC presentations included: 1. Early Screening Through Digital TasksWestern University – Adrian Owen, PhDUsing data from over 4,000 older adults, researchers applied machine learning to identify the two most predictive Creyos tasks for detecting age-related cognitive impairment. A screener using attention and working memory tasks matched mild cognitive impairment rates in a validation sample of over 9,000 adults, and correctly identified 100% of 14 participants with a clinical Alzheimer's disease diagnosis. The study positions Creyos as a powerful digital alternative to traditional dementia screening tools. 2. Genetics, Risk, and Online Testing in the PISA StudyQIMR Berghofer – Michelle Lupton, PhDThis study, conducted within the Prospective Imaging Study of Aging (PISA)—one of the world's largest cohorts focused on early Alzheimer's detection—validated the use of the Creyos platform for online cognitive testing in adults aged 42–75. Researchers compared self-administered Creyos assessments with traditional in-person testing and MRI-derived brain morphology measures. Findings showed strong alignment between online and in-person results, including associations with Alzheimer's-related brain changes and genetic risk. The study underscores the potential of online cognitive testing as a scalable, cost-effective tool for early detection and large-scale research in Alzheimer's disease. 3. Cognitive Resilience in Aging AdultsRotman Research Institute – Brian Levine, PhDWhy do some people maintain cognitive function despite age-related pathology or trauma? This study used Creyos to assess over 3,300 individuals across three cohorts. The Grammatical Reasoning task emerged as a potential marker of resilience—strong performance was associated with less excessive reliance on episodic memory strategies and greater resilience following PTSD. These insights point to reasoning ability as a potential buffer against cognitive decline. These studies demonstrate that Creyos is no stranger to rigorous science. The platform's role in the research being showcased at AAIC reflects not only continued trust among the global scientific community but also growing momentum in how cognitive data can support early detection, care planning, and treatment across settings. Creyos is used by healthcare providers in primary care, neurology, and behavioral health to screen for cognitive impairment, monitor longitudinal change, and inform care decisions. With nearly 20 million assessments completed and more than 10,000 providers actively using the platform, Creyos is reshaping how brain health is measured, bridging the gap between research insights and real-world care. About Creyos Creyos, formerly known as Cambridge Brain Sciences, is a pioneering healthcare technology company dedicated to transforming how healthcare providers assess and manage patient brain health. Supporting clinicians and health systems worldwide, the Creyos platform includes objective online tasks, digital behavioral health screeners, and condition-specific assessments that deliver actionable insights, promote early intervention, and enable evidence-based clinical decisions for various cognitive and behavioral health conditions, including dementia, ADHD, depression, anxiety, and others. Backed by 30 years of research and a normative database of over 85,000 participants, the FDA-registered Creyos platform has been published in over 400 peer reviewed studies and is recognized as a scientifically-validated solution for measuring and monitoring patient brain health. For more information about Creyos visit Media Contactcreyos@